About: Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis
Creator	Wang, Yan Cui, Min Wang, Zhong Gao, Yuan Yu, Gu, Zhi-Chun Le, Ke-Jia Lin, Hou-Wen Le K-Jia, Y-Xi Liu, Yang-Xi Liu, Zhang Z-Li Or, Yu E-Tian Yu, Yu E-Tian Yu, Yue-Tian Zhang, ; Zai-Li Zhang, Zai-Li Zhong, Han
Source	Elsevier; Medline; PMC
abstract	The rapidly progressing of coronavirus disease 2019 (COVID-19) pandemic has become a global concern. This meta-analysis aimed at evaluating the efficacy and safety of current option of therapies for severe acute respiratory syndrome (SARS), Middle Eastern respiratory syndrome (MERS) besides COVID-19, in an attempt to identify promising therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected patients. We searched PubMed, EMBASE, Cochrane Library, China National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database (VIP), and WANFANG DATA for randomized controlled trials (RCTs), prospective cohort, and retrospective cohort studies that evaluated therapies (hydroxychloroquine, lopinavir/ritonavir-based therapy, and ribavirin-based therapy, etc.) for SARS, MERS, and COVID-19. The primary outcomes were mortality, virological eradication and clinical improvement, and secondary outcomes were improvement of symptoms and chest radiography results, incidence of acute respiratory disease syndrome (ARDS), utilization of mechanical ventilation, and adverse events (AEs). Summary relative risks (RRs) and 95% confidence intervals (CIs) were calculated using random-effects models, and the quality of evidence was appraised using GRADEpro. Eighteen articles (5 RCTs, 2 prospective cohort studies, and 11 retrospective cohort studies) involving 4,941 patients were included. Compared with control treatment, anti-coronary virus interventions significantly reduced mortality (RR 0.65, 95% CI 0.44-0.96; I(2) = 81.3%), remarkably ameliorate clinical improvement (RR 1.52, 95% CI 1.05-2.19) and radiographical improvement (RR 1.62, 95% CI 1.11-2.36, I(2) = 11.0 %), without manifesting clear effect on virological eradication, incidence of ARDS, intubation, and AEs. Subgroup analyses demonstrated that the combination of ribavirin and corticosteroids remarkably decreased mortality (RR 0.43, 95% CI 0.27-0.68). The lopinavir/ritonavir-based combination showed superior virological eradication and radiographical improvement with reduced rate of ARDS. Likewise, hydroxychloroquine improved radiographical result. For safety, ribavirin could induce more bradycardia, anemia and transaminitis. Meanwhile, hydroxychloroquine could increase AEs rate especially diarrhea. Overall, the quality of evidence on most outcomes were very low. In conclusion, although we could not draw a clear conclusion for the recommendation of potential therapies for COVID-19 considering the very low quality of evidence and wide heterogeneity of interventions and indications, our results may help clinicians to comprehensively understand the advantages and drawbacks of each anti-coronavirus agents on efficacy and safety profiles. Lopinavir/ritonavir combinations might observe better virological eradication capability than other anti-coronavirus agents. Conversely, ribavirin might cause more safety concerns especially bradycardia. Thus, large RCTs objectively assessing the efficacy of antiviral therapies for SARS-CoV-2 infections should be conducted with high priority.
has issue date	2020-04-30(xsd:dateTime)
bibo:doi	10.1016/j.phrs.2020.104872
bibo:pmid	32360583
has license	no-cc
sha1sum (hex)	b0cfa8eb6ed4b972ec0283b05822bf3155055d7b
schema:url	https://doi.org/10.1016/j.phrs.2020.104872
resource representing a document's title	Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis
has PubMed Central identifier	PMC7192121
has PubMed identifier	32360583
schema:publication	Pharmacol Res
resource representing a document's body	covid:b0cfa8eb6ed4b972ec0283b05822bf3155055d7b#body_text
is schema:about of	named entity 'SARS' named entity 'COVID' named entity 'meta-analysis' named entity 'systematic review' named entity 'meta-analysis' named entity 'epidemic' named entity 'SARS' named entity 'epidemic' named entity 'bioavailability' named entity 'ribavirin' named entity 'kcal' named entity 'lopinavir/ritonavir' named entity 'virus' named entity 'PubMed' named entity 'control group' named entity 'New-castle' named entity 'clinical outcomes' named entity 'respiratory disease' named entity 'control group' named entity 'afebrile' named entity 'SARS' named entity 'SARS-CoV-2' named entity 'diarrhea' named entity 'STATA' named entity 'anemia' named entity 'hydroxychloroquine' named entity 'hydroxychloroquine' named entity 'control group' named entity 'corticosteroid' named entity 'interferon' named entity 'lopinavir/ritonavir' named entity 'intubation' named entity 'sample size' named entity 'lopinavir/ritonavir' named entity 'EC50' named entity 'virological' named entity 'adverse events' named entity 'total bilirubin' named entity 'creatinine' named entity 'lopinavir' named entity 'rescue therapy' named entity 'Saudi Arabia' named entity 'PROSPERO' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'arbidol' named entity 'control group' named entity 'statistically significant' named entity 'ACE2' named entity 'angiotensin-converting enzyme 2' named entity 'MERS' named entity 'therapeutic agents' named entity 'MERS' named entity 'intensive care unit' named entity 'lopinavir/ritonavir' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'endosomal' named entity 'remdesivir' named entity 'control group' named entity 'CNKI' named entity 'leukopenia' named entity 'SARS-CoV-2' named entity 'Middle Eastern respiratory syndrome' named entity 'SARS-CoV'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software